About
KeraX Venture Lab is an impact-first venture lab that focuses on sustainable innovations for corneal and ocular diseases and affecting low and middle income countries. We seek to transform breakthrough ideas into scalable ventures that directly support KeraLink International’s mission. Our strategic edge is our emphasis on frugal innovation: engineering high-impact simplicity for the world’s most resource-constrained environments.
We are reimagining corneal health and making sight-saving technologies accessible, scalable and sustainable.
We do this by addressing systemic barriers to corneal care:
-
Scarcity: There is a shortage of donor corneas and trained corneal surgeons
-
High Complexity and Cost: Existing solutions are complex and out of reach for most
-
Inadequate Diagnostic Tools prevent many patients from receiving care until it is too late.
We believe that corneal blindness is largely preventable or treatable with
-
Timely diagnosis
-
Early intervention, and
-
Access to appropriate therapies.
KeraX pursues an India-first, global-next strategy.
-
India is the country with the highest corneal disease burden; it also offers a strong eye care infrastructure, favorable regulatory pathways and a “Make in India” innovation ecosystem.
-
KeraX established a presence at Pune’s Venture Center, India’s premier medical innovation incubator, supporting on-the-ground prototyping, testing, and manufacturing pathways.

Our Story
Launched in January 2025, KeraX Venture Lab operates under a venture studio model designed to validate and scale affordable technologies. By leveraging our expertise in corneal health, we explore promising innovations and accelerate their path to sustainable impact.
KeraX is born out of the legacy of KeraLink International (KLI), its non-profit parent organization. KLI was founded as the Medical Eye Bank of Maryland in 1962. In the 1980s, KLI under the name Tissue Banks International assisted in opening 48 eye banks in 24 countries, becoming the world’s largest ocular tissue supplier. In the 1990s, KLI helped eliminate waiting lists for cornea transplants in the US, effectively eradicating untreated corneal blindness in the U.S. However globally, for every 70 people who need a corneal transplant, there is only 1 tissue available.
Realizing the mismatch between the scope of corneal blindness and the eye bank infrastructure scale up needed, KLI sold its eye banks in 2019 to focus solely on harnessing the power of new and emerging technologies to eradicate corneal blindness globally in ways not possible before.
Today, KeraX as the impact-first venture lab arm of KLI focuses on sustainable innovations for corneal and ocular diseases affecting low and middle income communities globally. KeraX makes select seed investments and develops in house ventures targeting underinvested gaps in the treatment landscape.
Our Vision
We Envision a World Free of Avoidable Corneal Blindness.
Where cutting-edge, affordable solutions reach every corner of the globe, ensuring that no individual is denied the right to sight. By uniting clinicians, technology innovators, social entrepreneurs, and impact capital, we aim to turn this vision into a reality, making comprehensive eye care accessible and sustainable for all.

Innovation
Equity
Respect
Empathy
Collaboration
Growth Mindset
The Team
.jpg)
Michelle Bockman, President
Ex-GE Health, Ex-President Stanley X, & HP; BS Mechanical Engineering, Missouri University of Science & Technology.
.png)
David Green, CTO and CIO
Pioneer social entrepreneur in low-cost cataract surgery (intraocular lenses now used worldwide); founder at Aurolab, MacArthur "Genius" Award, MPH, U of Michigan

Aaron Chang, Director of Product Development
Biomedical engineer with medtech startup experience (PlenOptika, Dascena, Alliance for AI in Healthcare); MBA Duke Fuqua, MSE Johns Hopkins

Allie Sibole, Principal Engineer
Device design lead (light therapy, hardware); prior roles at Medtronic, PATH, Johnson & Johnson; MSE Johns Hopkins
.jpg)
Dr. Yogesh Shelke, Technology Venture Lead
Physician-engineer bridging innovation & local implementation; leadership across healthcare & medtech ventures; MTech and MBA IIT Bombay, MBBS Surgery Maharashtra University of Health Sciences

Elisabeth Ayvazian
Impact investment professional with a mix of corporate and social sector experience. Experience at Deutsche Bank and Citi. Co-founded Deutsche Bank Eye Fund.
Our Board
Our board consists of leading corneal specialists and industry veterans.
Chair
Chris Helmrath, MBA

Managing Director of SC&H Capital. MBA Loyola University Maryland, BS Economics, Miami University.
Director
Roberto Pineda, MD

Director, Keratorefractive Surgical Service, Massachusetts Eye and Ear Infirmary; M.D. University of Minnesota Medical School.
Director
Brian Levy, OD, MSc
.jpg)
Former CEO of InflammX Therapeutics (acquired). Doctor of Optometry, University of California, Berkeley; MSc in Comparative Anatomy and Physiology of the Eye, University of Waterloo.
Director
Nakul Shekhawat, MD, MPH, ScM
.jpg)
Ophthalmologist, cornea surgeon, and clinical trials expert, Johns Hopkins Wilmer Eye Institute; MD, Vanderbilt University; graduate degrees in epidemiology, biostatistics, and clinical trials, Johns Hopkins Bloomberg School of Public Health.
Director
Bobby George, MBA
.jpeg)
Senior Vice President (Abbott), and Accenture. BA Chemical Engineering, National Institute of Technology Rourkela; MBA from the International Management
Institute, India.
Director
Dr. Manisha Premnath

Chief Operating Officer
of Venture Center – India’s leading science-based business and inventive enterprise incubator; PhD and MSE in biotechnology from Savitribai Phule Pune University
President
Michelle Bockman
.jpg)
CEO KeraLink International, ex-President Stanley X, ex-GE & HP; BS Mechanical Engineering, Missouri University of Science & Technology.